LYRICA CR CV

Indications for LYRICA CR:

Neuropathic pain associated with diabetic peripheral neuropathy (DPN). Postherpetic neuralgia (PHN).

Adult:

Swallow whole. Take once daily after evening meal. DPN: initially 165mg daily, may increase to max 330mg/day within 1 week. PHN: initially 165mg daily, may increase to 330mg daily within 1 week; max 660mg/day if insufficient relief after 2–4wks. Conversion from Lyrica capsules, oral soln: see full labeling. For all: renal impairment (CrCl 30–60mL/min): reduce dose (see full labeling); (CrCl <30mL/min or hemodialysis): dose with Lyrica.

Children:

Not established.

Warnings/Precautions:

Avoid abrupt cessation (taper over ≥1 week). Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. CHF. Ocular conditions. Diabetes (monitor skin integrity). Suicidal tendencies (monitor). Pregnancy. Nursing mothers: not recommended.

Interactions:

Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.

See Also:

LYRICA

LYRICA ORAL SOLUTION

Pharmacological Class:

Alpha-2 delta ligand.

Adverse Reactions:

Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention), infection, asthenia, paresthesias, headache, fatigue; elevated creatine kinase, decreased platelets, arrhythmias (PR prolongation), male-mediated teratogenicity; may be tumorigenic.

Note:

Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.

How Supplied:

Caps—90; CR tabs—30; Soln—16oz